ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AVXL

Anavex Life Sciences (AVXL)

Anavex Life Sciences Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AVXL
DateTimeSourceHeadlineSymbolCompany
02/26/20247:30AMGlobeNewswire Inc.Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care ConferenceNASDAQ:AVXLAnavex Life Sciences Corporation
02/23/20246:05AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVXLAnavex Life Sciences Corporation
02/23/20246:04AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVXLAnavex Life Sciences Corporation
02/23/20246:04AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVXLAnavex Life Sciences Corporation
02/23/20246:03AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVXLAnavex Life Sciences Corporation
02/23/20246:03AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVXLAnavex Life Sciences Corporation
02/07/20244:31PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVXLAnavex Life Sciences Corporation
02/07/20247:30AMGlobeNewswire Inc.Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business UpdateNASDAQ:AVXLAnavex Life Sciences Corporation
02/01/20247:30AMGlobeNewswire Inc.Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024NASDAQ:AVXLAnavex Life Sciences Corporation
01/25/20245:01PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AVXLAnavex Life Sciences Corporation
01/24/20247:30AMGlobeNewswire Inc.Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in HumansNASDAQ:AVXLAnavex Life Sciences Corporation
01/16/20247:30AMGlobeNewswire Inc.Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in SchizophreniaNASDAQ:AVXLAnavex Life Sciences Corporation
01/12/20248:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVXLAnavex Life Sciences Corporation
01/08/20247:30AMGlobeNewswire Inc.Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental DisordersNASDAQ:AVXLAnavex Life Sciences Corporation
01/03/20247:30AMGlobeNewswire Inc.Anavex to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AVXLAnavex Life Sciences Corporation
01/02/20248:00AMGlobeNewswire Inc.Anavex Life Sciences Provides an Update on Rett Syndrome ProgramNASDAQ:AVXLAnavex Life Sciences Corporation
12/20/20237:30AMGlobeNewswire Inc.Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett SyndromeNASDAQ:AVXLAnavex Life Sciences Corporation
12/19/20237:30AMGlobeNewswire Inc.Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s DiseaseNASDAQ:AVXLAnavex Life Sciences Corporation
11/27/20234:30PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AVXLAnavex Life Sciences Corporation
11/27/20238:00AMGlobeNewswire Inc.Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business UpdateNASDAQ:AVXLAnavex Life Sciences Corporation
11/27/20236:29AMIH Market NewsMonday’s Wall Street Highlights: Walmart, Disney, Lloyds Banking, Mitsui Financial, HSBC, and moreNASDAQ:AVXLAnavex Life Sciences Corporation
11/24/20238:00AMGlobeNewswire Inc.Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023NASDAQ:AVXLAnavex Life Sciences Corporation
11/22/20238:00AMGlobeNewswire Inc.Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Insomnia or AnxietyNASDAQ:AVXLAnavex Life Sciences Corporation
11/20/20238:00AMGlobeNewswire Inc.Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency (EMA)NASDAQ:AVXLAnavex Life Sciences Corporation
11/06/20238:00AMGlobeNewswire Inc.Anavex Life Sciences Appoints Senior VP of Regulatory AffairsNASDAQ:AVXLAnavex Life Sciences Corporation
10/25/20238:00AMGlobeNewswire Inc.Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX®3-71 to Prevent Cognitive Decline in Alzheimer’s DiseaseNASDAQ:AVXLAnavex Life Sciences Corporation
09/14/20237:30AMGlobeNewswire Inc.Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows NeurodegenerationNASDAQ:AVXLAnavex Life Sciences Corporation
09/12/20237:30AMGlobeNewswire Inc.Anavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman of the Scientific Advisory BoardNASDAQ:AVXLAnavex Life Sciences Corporation
08/08/20234:30PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVXLAnavex Life Sciences Corporation
08/08/20237:30AMGlobeNewswire Inc.Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial ResultsNASDAQ:AVXLAnavex Life Sciences Corporation
 Showing the most relevant articles for your search:NASDAQ:AVXL
NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com